About Tris Pharma
Tris Pharma is a Healthcare company based in Monmouth Junction (United States) founded in 2000 by Ketan Mehta. Technology-based oral extended release pharmaceutical products are developed. Tris Pharma has raised $125 million across 3 funding rounds from investors including NIH and Deerfield. The company has 441 employees. Tris Pharma has completed 1 acquisition, including NextWave Pharmaceuticals. Its chief executive, as recorded, is Ketan Mehta. Tris Pharma offers products and services including LiquiXR Technology, ADHD Therapies, and Pain Therapies. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Tris Pharma, Inc. Its competitors include Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2000 and based in Monmouth Junction, United States, Tris Pharma operates in the pharmaceutical sector with a focus on oral extended release formulations. The lead product, TRN-124, is an extended-release oral suspension for cough and cold treatment, with NDA submission approved in clinical development. Additional candidates are advanced through various clinical phases by the company, led by founder and CEO Ketan Mehta.
- Headquarters Monmouth Junction, United States
- Employees 441
- Founders Ketan Mehta
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website trispharma.com
- Social LinkedIn Facebook Instagram
- Legal Name Tris Pharma, Inc.
- Total Equity Funding$125M (USD)
in 3 rounds
- InvestorsNIH
& 1 more
- Employee Count441
- Investments & Acquisitions
Products & Services of Tris Pharma
Tris Pharma offers a comprehensive portfolio of products and services, including LiquiXR Technology, ADHD Therapies, and Pain Therapies.
Proprietary system for creating patient-friendly pharmaceuticals.
Treatments enhancing care for adults and children with ADHD.
Investigational compounds for moderate-to-severe pain management.
Funding Insights of Tris Pharma
Tris Pharma has successfully raised a total of $125M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $125M
- Total Rounds 3
- First Round $125M
(Sep 2018)
- Investors Count 2
All 3 funding rounds of Tris Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Tris Pharma
Tris Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Tris Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tris Pharma
96 people are tracked at Tris Pharma (21 in leadership, 75 in team); the tracked headcount is 441.
| Name | Role | Group |
|---|---|---|
Ketan Mehta | Founder & CEO | Leadership |
Scott Adams | Director - National Accounts | Leadership |
Scott Nemitz | Vice President Of Sales | Leadership |
Steve Levandowski | Senior Regional Sales Director | Leadership |
Janet Penner | President, Generic Division | Leadership |
James Hackworth | Chief Business Officer | Leadership |
Nicholas Cappuccino | Chief Quality Officer, SVP of Quality & Compliance | Leadership |
Peter Ciano | CFO | Leadership |
Nancy O'Connor | Executive Director Financial Planning & Analysis | Leadership |
Tejendra Rao | Vice President Supply Chain | Leadership |
Kevin Walker | Vice President, Generic Sales | Leadership |
Marc Lesnick | Chief Development Officer | Leadership |
Michael Magee | Vice President, Quality And Compliance | Leadership |
Brian Muhal | Director Trade & Distribution | Leadership |
Franchesca M. Fowler | General Counsel, Vice President And Chief Compliance Officer | Leadership |
Ketan Saparia | Associate Director, DEA And Supply Chain | Leadership |
Jisheng Zhu | QA Director | Leadership |
Andi B. Robbins | Senior Director, Quality Compliance | Leadership |
Saumya Mehta | Senior Director, Business Development | Leadership |
Andrea Nelson | Associate Director, Business Development | Leadership |
76 more people are available in the full profile.
Complete people profiles for Tris Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tris Pharma
Tris Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NextWave Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical products for CNS and ADHD treatments are developed. | nextwavepharma.com | Cupertino, United States | 2005 | Sep 2018 | •••• |
Complete acquisition details for Tris Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Tris Pharma
4 dated milestones of Tris Pharma across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Tris Pharma is founded.
- Funding First funding round of $125.0M.
- Acquisition Acquires NextWave Pharmaceuticals.
- Funding Latest funding round, Grant,.
Competitors of Tris Pharma
Tris Pharma has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. |
Detailed competitors of Tris Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tris Pharma
The website of Tris Pharma (trispharma.com) receives about 9.7K visits a month and ranks #2,135,145 among all websites worldwide, #2,899 in Biotechnology and Pharmaceuticals.
- Monthly visits9.7K
▼ 7.5% vs previous month
- Unique visitors4.8K
per month
- Global rank#2,135,145
among all websites
- Category rank#2,899
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.9
- Average visit55 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Tris Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| actavis.com | 100% | View details | |||
tillotts.com | tillotts.com | 87% | #4,030,052 | – | |
leo-pharma.us | leo-pharma.us | 87% | #5,900,667 | – | |
| worldpharmanews.com | 87% | View details | |||
| innate-pharma.com | 87% | 10.5K | #2,074,647 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Tris Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Tris Pharma (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tris Pharma
Complete news archive for Tris Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tris Pharma
Tris Pharma was founded in 2000 and raised its 1st funding round 18 years after it was founded.
Tris Pharma is headquartered in Monmouth Junction, United States. It is registered at Monmouth Junction, New Jersey, United States.
Ketan Mehta is the CEO of Tris Pharma, as recorded in our data. They have also founded this company.
Tris Pharma is a funded company, having raised a total of $125M across 3 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $125M, raised on Sep 2018.
Tris Pharma has 441 employees.
Founded in 2000 and based in Monmouth Junction, United States, Tris Pharma operates in the pharmaceutical sector with a focus on oral extended release formulations. The lead product, TRN-124, is an extended-release oral suspension for cough and cold treatment, with NDA submission approved in clinical development. Additional candidates are advanced through various clinical phases by the company, led by founder and CEO Ketan Mehta.
Tris Pharma's top competitors include PTC Therapeutics, Neurocrine and Biohaven Pharmaceutical.
Tris Pharma offers LiquiXR Technology, ADHD Therapies, and Pain Therapies.
Tris Pharma has made 1 acquisition, including NextWave Pharmaceuticals.
Tris Pharma operates through Tris Pharma, Inc..